Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 11/20 | 0.63 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271236 | 0.97 | PLK1 (0.60) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2275929 | 0.94 | KMT2A (0.62) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2278451 | 0.88 | LTC4S (0.60) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2271080 | 0.86 | MEN1 (0.56) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2271421 | 0.86 | DHODH (0.63) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2273122 | 0.86 | PLK1 (0.57) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2270925 | 0.86 | PLK1 (0.57) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2271422 | 0.86 | LTC4S (0.74) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2274700 | 0.85 | MEN1 (0.55) | PLK1PLK3MEN1PKMKMT2A | |
| SCHEMBL2271182 | 0.85 | PLK1 (0.53) | PLK1PLK3MEN1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | PLK1 4227/4885PLK3 3893/4885MEN1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.